Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

What Was Tested

The paper reports a study of Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.

To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.

Who Took Part

According to the abstract, 203 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, multicenter and parallel-group.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

As a double-blind Amylin (Islet Amyloid Polypeptide) study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Amylin (Islet Amyloid Polypeptide), giving a reference point.

More than one site took part, so the patients came from several places.

What Was Measured

PubMed files the paper under topics including Amyloid, Biomarkers, Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Type 2 and Fructosamine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) in 203 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.